This handout is for obesity + obstructive sleep apnea (osa) hypertensive emergency (resistant-htn phenotype with sympathetic + raas overdrive; cpap + weight loss + mra central to long-term control). Your care team identified this based on: known resistant htn (≥3 antihypertensives at max tolerated doses including diuretic, bp still uncontrolled) + obesity (bmi ≥30) + osa features (witnessed apnea, snoring, daytime sleepiness, morning headache) presenting with sbp ≥180/dbp ≥120 + end-organ damage.
Other reasons your team may use this plan: early-morning bp surge + witnessed nocturnal apnea + non-dipping abpm pattern + resistant htn despite ≥3 agents; bmi ≥40 (class iii obesity) + uncontrolled htn + cor pulmonale or right-heart strain on echo.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| nicardipine | 5 mg/h IV titrate q5-15 min by 2.5 mg/h, max 15 mg/h | IV | continuous infusion | AHA 2025 HTN emergency Class I — first-line non-dissection adult HTN crisis; predictable titration, minimal reflex tachycardia |
| labetalol | 10-20 mg IV q10 min titrate to SBP <160 (max 300 mg cumulative); OR 0.5-2 mg/min infusion | IV | PRN bolus or continuous | AHA 2025 — mixed α/β useful in OSA-driven sympathetic crisis; addresses both vasoconstriction and tachycardia |
| nitroglycerin | 5-200 mcg/min IV titrate q3-5 min | IV | continuous | Vasodilator + venodilator + coronary vasodilator; useful when LV-failure/pulm-edema overlay present (common in obesity-OSA HFpEF) |
| spironolactone | 25 mg PO daily, titrate to 50 mg | PO | daily | PATHWAY-2 (Williams Lancet 2015 PMID 26414968) — spironolactone superior to doxazosin and bisoprolol as 4th-line agent for resistant HTN; effect amplified in OSA + PA-enriched populations |
| chlorthalidone | 12.5-25 mg PO daily | PO | daily | Thiazide-like preferred over HCTZ for resistant HTN (longer half-life, better 24-h BP control); PATHWAY-2 + ALLHAT |
| amlodipine | 5-10 mg PO daily | PO | daily | CCB pillar of standard 3-drug + MRA resistant-HTN regimen (ACC/AHA 2025) |
| lisinopril | 10-40 mg PO daily | PO | daily | RAAS-blockade pillar; particularly useful in obesity-OSA where RAAS activation is mechanistic |
| semaglutide | 0.25 mg SC weekly × 4 wk → 0.5 mg × 4 wk → 1 mg × 4 wk → 1.7 mg → 2.4 mg SC weekly maintenance | SC | weekly | STEP-1 (Wilding NEJM 2021 PMID 33567185) ~15% weight loss; STEP-HFpEF (Kosiborod NEJM 2023 PMID 37877559) cardiometabolic benefit in obesity-related HFpEF; secondary BP reduction via weight loss |
| tirzepatide | 2.5 mg SC weekly × 4 wk titrate q4 wk to max 15 mg | SC | weekly | SURMOUNT-1 — superior weight loss to semaglutide; BP reduction signal |
| clonidine | 0.1 mg PO BID titrate to 0.3 mg BID; transdermal Catapres-TTS-3 0.3 mg/24h alternative | PO + transdermal | BID + weekly patch | Add-on if MRA + α-blocker insufficient; AVOID abrupt discontinuation (rebound HTN risk — cross-link clonidine-withdrawal engine) |
| CPAP / BiPAP for OSA / OHS | Auto-CPAP 5-15 cmH2O range; titrate to AHI <5 + SpO2 ≥90% across night; BiPAP (IPAP 12-20 / EPAP 6-10) for OHS overlap | mask | every night ≥4 h/night ≥70% of nights | CRESCENDO (Pedrosa 2014 PMID 24571566) + Schein meta-analysis (PMID 25096531) — CPAP reduces 24-h SBP/DBP by ~7/5 mmHg in resistant HTN with OSA; greatest benefit in severe OSA + adherent users |
| Bariatric surgery (RYGB or sleeve gastrectomy) | Per surgical evaluation | surgical | one-time | Sustained 25-30% weight loss + HTN remission in 50-70%; preferred over medical-only therapy for severe obesity with refractory HTN |
| Renal denervation (RDN) | Bilateral renal artery RF or US ablation per SPYRAL/RADIANCE protocol | endovascular | one-time | SPYRAL HTN-OFF MED (Böhm Lancet 2020 PMID 32562445) — sustained ~10/5 mmHg reduction; FDA-approved 2023 for adjunctive use |
| Weight loss + DASH diet + exercise | Target 5-10% weight loss; DASH diet; 150 min/week moderate aerobic + 2 sessions resistance | lifestyle | daily | Look AHEAD (Wing NEJM 2013 PMID 23796131) + ACC/AHA 2025 lifestyle recommendation; foundation of all obesity-related HTN management |
Plan: Obesity + OSA HTN crisis — acute IV nicardipine + labetalol; CPAP/BiPAP initiation; long-term PATHWAY-2 ladder (MRA + thiazide-like) + GLP-1 RA + bariatric surgery + renal denervation as adjunct
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Sleep medicine 2-4 weeks post-d/c for CPAP titration + adherence verification; cardiology + nephrology for resistant HTN; endocrine if PA/pheo positive; nutrition + bariatric medicine for weight management (semaglutide titration over 16 weeks; bariatric surgery referral if BMI ≥40 refractory); home BP monitoring (target <130/80 if standard, <125/75 if CKD/DM); CPAP adherence target ≥4 h/night ≥70% of nights with AHI <5 on therapy; weight loss target 5-10% in 6-12 months → reassess HTN regimen; renal denervation referral if BP refractory after maximal medical + lifestyle therapy + secondary causes excluded
Guideline: 2025 ACC/AHA HTN Guideline (Whelton) + AASM 2017 OSA (Kapur PMID 28162150) + PATHWAY-2 (Williams Lancet 2015 PMID 26414968) + STEP-HFpEF (Kosiborod NEJM 2023 PMID 37877559)